fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Nippon India PHARMA Fund

Nippon India PHARMA Fund - G

NAV  ₹186.208 ↑ 4.61  (2.54 %) as on 29 May 20

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 20.1% since its launch.  Ranked 35 in Sectoral category.  Return for 2019 was 1.7% , 2018 was 3.6% and 2017 was 7.6% .

Below is the key information for Nippon India Pharma Fund

NAV as on 29 May 20₹186.208 ↑ 4.61  (2.54 %)
Net Assets (AUM) as on 30 Apr 2020 ₹2,851 Cr.
Launch Date5 Jun 2004
CategoryEquity - Sectoral
Rating
TypeOpen Ended Fund
RiskHigh
AMCNippon Life Asset Management Ltd.
Alpha Ratio8.11
Expense Ratio2.33 %
Sharpe Ratio0.556
Information Ratio1.68
BenchmarkNot Available
Min Investment ₹5,000
Min SIP Investment ₹100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 May 20

DurationReturns
1 Month 3.5%
3 Month 19.5%
6 Month 22.7%
1 Year 28.6%
3 Year 16.5%
5 Year 6.4%
10 Year
15 Year
Since launch 20.1%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

YearReturns
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
2014 49.5%
2013 20.9%
2012 34.8%
2011 -11%

Growth of 10k Over Years

DateValue
31 May 15₹10,000
31 May 16₹9,696
31 May 17₹8,897
31 May 18₹9,891
31 May 19₹10,545
31 May 20₹13,637
Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset ClassValue
Cash3.94%
Equity96.47%
Nippon India PHARMA Fund Asset Allocation

Sector Allocation

SectorValue
Health Care96.47%
Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

NameGlobal IndustryHoldingValueQuantity
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMA
Drug Manufacturers - Specialty & Generic11%₹313 Cr5,000,000
↑ 500,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | 500124
Drug Manufacturers - Specialty & Generic10%₹295 Cr750,000
↓ -25,000
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
Drug Manufacturers - Specialty & Generic10%₹293 Cr6,300,976
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
Drug Manufacturers - Specialty & Generic9%₹257 Cr1,100,075
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
Drug Manufacturers - General8%₹224 Cr3,800,000
↓ -1,200,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
Drug Manufacturers - Specialty & Generic7%₹209 Cr2,500,025
↑ 600,000
Syngene International Ltd (Healthcare)
Equity, Since 30 Nov 17 | 539268
Biotechnology5%₹139 Cr4,300,000
↑ 300,000
Sanofi India Ltd (Healthcare)
Equity, Since 30 Jun 04 | 500674
Drug Manufacturers - General5%₹136 Cr175,000
↓ -5,000
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Aug 18 | 532843
Medical Care Facilities5%₹135 Cr10,603,541
↑ 1,510,184
Thyrocare Technologies Ltd (Healthcare)
Equity, Since 31 May 16 | THYROCARE
Diagnostics & Research5%₹129 Cr2,539,512
↑ 88,626
1 - 10 of 23
Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Fund Managers

NameSinceTenure
Sailesh Raj Bhan1 Apr 0515.01 Yr.
Kinjal Desai25 May 181.85 Yr.

Custodians

CompanyAddress
Deutsche Bank AGDeutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Private Limited
Address"KARVY HOUSE",46, Avenue 4, Street No.1,,Banjara Hills,
FAX91-40-23311968
Emailmailmanager@karvy.com

Administrator Companies

CompanyAddress
Nippon India Mutual Fund9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

CompanyAddress
Haribhakti & Co. Chartered Accountants42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and PlanNAV6 Month1 Year3 Year5 Year
Nippon India Pharma Fund
Normal Dividend, Payout
₹58.5822
↑ 1.45
21.52 %27.38 %15.72 %5.97 %
Nippon India Pharma Fund
Normal Dividend, Reinvestment
₹58.5822
↑ 1.45
21.52 %27.38 %15.72 %5.97 %
Nippon India Pharma Fund
Growth
₹186.208
↑ 4.61
22.71 %28.64 %16.49 %6.4 %
Data as on 29 May 20

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.